| Literature DB >> 33894041 |
Dongyuan Wang1,2, Yihui Liu1,2, Fang Zeng1,2, Chen Shi1,2, Fang Cheng1,2, Yong Han1,2, Yu Zhang1,2.
Abstract
BACKGROUND: Fangcang Hospitals (cabin hospitals) played a key role in isolation and control of the infection sources during COVID-19 epidemic. Many patients at Fangcang Hospitals had complications or mental stress. As the doctors, nurses and paramedics presented in the emergency, there was a growing demand for clinical pharmacists to provide pharmaceutical care for the affected patients with chronic diseases via telemedicine.Entities:
Mesh:
Year: 2021 PMID: 33894041 PMCID: PMC8250255 DOI: 10.1111/ijcp.14271
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 3.149
Self‐reported questionnaire of inpatients at Jianghan Fangcang Hospital
The discharge patients’ questionnaire at Jianghan Fangcang Hospital
Demographics and clinical characteristics of patients
| Characteristics | No. (%) of patients (n = 349) |
|---|---|
| Gender | |
| Women | 201 (57.6%) |
| Men | 148 (42.4%) |
| Age (y) | 45.5 ± 10.6 |
| Clinical symptoms with COVID‐19 | |
| Fever (temperature ≥37.3°C) | 278 (79.7%) |
| Cough | 211 (60.5%) |
| Pharyngalgia, Myalgia, headache | 200 (57.3%) |
| Shortness of breath | 149 (42.7%) |
| Chest distress | 134 (38.4%) |
| Diarrhoea | 125 (35.8%) |
| Nausea and vomiting | 87 (24.9%) |
| Dyspnoea | 85 (24.4%) |
| Eye symptoms | 64 (18.3%) |
| Sneeze | 60 (17.2%) |
| Rhinobyon | 49 (14.0%) |
| Comorbidity | |
| Hypertension | 45 (12.9%) |
| Hyperlipidaemia | 32 (9.2%) |
| Thyroid disease | 31 (8.9%) |
| Diabetes | 25 (7.2%) |
| Heart disease | 12 (3.4%) |
| Nephropathy | 6 (1.7%) |
| Cancer | 4 (1.1%) |
| Others | 44 (12.6%) |
| None | 214 (61.3%) |
Medications for COVID‐19 patients
| Drug names | No. (%) of patients (n = 349) |
|---|---|
| Lianhua Qingwen Granule | 324 (92.8%) |
| Oseltamivir | 288 (82.5%) |
| Arbidol | 247 (70.8%) |
| Ribavirin | 17 (4.9%) |
| Interferon | 6 (1.7%) |
| Moxifloxacin | 255 (73.1%) |
| Cefdinir | 128 (36.7%) |
| Levofloxacin | 112 (31.1%) |
| Amoxicillin | 22 (6.3%) |
| Chinese medicine | 226 (64.8%) |
| Couh medicine | 31 (8.29%) |
| Ibuprofen | 48 (12.83%) |
| Hypotensive drugs | 45 (12.9%) |
| Hypoglycaemic agents | 25 (7.2%) |
| Antilipemic | 32 (9.2%) |
| Thyoid drugs | 31 (8.9%) |
| Anti‐cancer drugs | 4 (1.1%) |
| Drugs for heart diseases | 12 (3.4%) |
Reported adverse drug reaction by COVID‐19 patients
| Symptoms | No. (%) of patients (n = 349) |
|---|---|
| Nausea | 74 (21.2%) |
| Diarrhoea | 73 (20.9%) |
| Fatigue | 70 (20.1%) |
| Sleeplessness | 38 (10.9%) |
| Skin pruritus | 33 (9.5%) |
| Vomiting | 32 (9.2%) |
| Constipation | 13 (3.7%) |
| Dysuria | 13 (3.7%) |
| Others | 19 (5.4%) |
| None | 88 (25.2%) |
Questions from COVID‐19 patients and pharmacists’ medication interventions
| Question classification | No. (%) of questions (n = 196) |
|---|---|
| COVID‐19‐related problems | 57 (29.1%) |
| Initial symptoms, disease progression, sequelae, relapse | 19 (9.7%) |
| Complications | 20 (10.2%) |
| Disease detection index | 18 (9.2%) |
| COVID‐19 medication‐related problems | 82 (41.8%) |
| Drug selection problems and drug precautions | 35 (17.9%) |
| Adverse drug reaction | 16 (8.2%) |
| Treatment of asymptomatic infections | 14 (7.1%) |
| Drug interaction problem | 11 (5.6%) |
| Basic chronic disease‐related problems | 24 (12.2%) |
| Diabetes‐related problems, such as medication reconciliation | 9 (4.6%) |
| Cardiovascular and cerebrovascular diseases related problems | 10 (5.1%) |
| Other chronic disease‐related problems | 5 (2.5%) |
| Life‐related problems | 15 (7.7%) |
| Diet‐ and nutrition‐related problems | 4 (2.0%) |
| Exercise at Fangcang hospital | 2 (1.0%) |
| Others | 9 (4.6%) |
| Matters of discharge | 18 (9.2%) |
| Discharge‐related problems | 11 (9.2%) |
| Medications out of hospital | 3 (1.5%) |
Satisfaction of clinical pharmaceutical care for patients (n = 78)
| Survey items | Great No. (%) | Good No. (%) | Fair No. (%) | Poor No. (%) |
|---|---|---|---|---|
| The knowledgement of clinical pharmacists before servicePlease consider changing the word “knowledgement” here and subsequent occurrences. | 6.4% | 5.1% | 14.1% | 74.4% |
| The knowledgement of clinical pharmacists after service | 9.0% | 35.9% | 42.3% | 12.8% |
| Patients’ recognition | 46.2% | 42.3% | 7.7% | 3.9% |
| Patients’ benefit on rational drug use | 38.5% | 52.6% | 0 | 9.0% |
| Satisfaction with this service | 66.7% | 18.0% | 14.1% | 1.3% |
| Necessary of this service | 62.8% | 32.1% | 5.1% | 0 |
| Benefit on psychological help | 16.7% | 43.6% | 26.9% | 12.8% |
| Usefulness of pharmaceutical care for outcome of disease | 21.8% | 43.6% | 33.3% | 1.3% |